Abstract
With the introduction of new drugs like tirzepatide, the relationship between metabolic treatments and oncology has attracted a lot of interest lately. Tirzepatide, a dual agonist of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors, has shown promising results in the treatment of type 2 diabetes and obesity, two disorders associated with an increased risk of gastric cancer. The purpose of this study is to examine tirzepatide's possible effects on the development and prevention of stomach cancer. We investigate the therapeutic potential of tirzepatide and pinpoint areas in need of more investigation by looking at the body of existing literature and mechanistic insights . The results emphasize the need [1], [3] for more research into tirzepatide's direct impact on gastric carcinogenesis as well as its complex modes of action and function in modifying risk factors.